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Lea Ann Chen,New York University Langone Medical Center
Fecal microbiota transplantation (FMT) for patients with
multiply recurrent Clostridium difficile (C. difficile) infections
despite standard medical treatment is considered both
effective, with approximately 90% cured (Aroniadis et al.
2016), and acceptable regarding short-term safety con-
cerns. Doctors who perform FMT often also receive
requests for the treatment from patients suffering from a
range of other conditions, including irritable bowel syn-
drome and inflammatory bowel diseases, such as Crohn’s
disease and ulcerative colitis. Sometimes patients request
FMT prior to accepting standard treatment options, and
thus seem to prefer it to standard of care. Other patients
request FMT for non-gastrointestinal disorders, in which
disease etiology and activity may be more tenuously
linked to gut bacteria. These examples highlight the grow-
ing popularity of FMT, which in turn gives rise to concerns
regarding appropriate informed consent for the procedure.
For patients who qualify for FMT, doctors should explain
the investigational nature of the treatment, ensure a dis-
cussion of its potential long-term risks as part of the
informed consent process (Food and Drug Administration
2013), and at minimum discuss all U.S. Food and Drug
Administration (FDA)-approved treatment alternatives.
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The FDA has chosen to regulate human feces as a
drug—specifically, as a biological product (e.g., vaccines,
blood products), but has not yet approved FMT for any
medical indication. However, in light of the growing rate
and severity of C. difficile infections (CDIs) and the promis-
ing early data from FMT, in 2013 the FDA announced its
decision to exercise enforcement discretion when doctors
provide FMT for CDIs that do not respond to standard
treatment (typically interpreted as multiply recurrent and
refractory CDIs). For all other indications, FMT can only
be used under an investigational new drug (IND) applica-
tion (i.e., in the context of a clinical trial).
In being condoned by the FDA for the treatment of cer-
tain CDIs and gradually adopted by physicians, the use of
FMT has resembled the way in which some surgical tech-
niques are introduced in clinical practice: not based on
large-scale clinical trial data, but rather on accumulating
experience and case reports. In cases of recurrent and
refractory CDIs, FMT can be considered in the “transition
zone” (Schwartz 2014) between experimental research and
standard of care. Although innovative interventions are
usually regulated less stringently than new drugs or bio-
logical products, their “experimental” nature does imply
special ethical requirements for informed consent. While
there are no formal standards for the content of informed
consent for “transition zone” interventions, it is generally
accepted that such discussions should include the follow-
ing elements: the innovative nature of the procedure, the
provider’s experience with the procedure, the risks and
benefits including unknown risks, the (lack of) evidence,
and alternatives to the innovative intervention (Broekman,
Carriere, and Bredenoord 2016). As the FDA states in its
enforcement policy: “The consent should include, at a min-
imum, a statement that the use of FMT products to treat C.
difficile is investigational and a discussion of its potential
risks” (FDA 2013). We are concerned that these standards
for informed consent may not be consistently met in clini-
cal practice.
Yonghui Ma and colleagues (2017), likewise, identify
informed consent as one of the main ethical issues in FMT,
but do so for the wrong reasons. They argue that it would
be “extremely difficult” to obtain informed consent for
FMT from patients with inflammatory bowel disease
(IBD)—“prime candidates for this treatment”—as patients
with IBD are sometimes young and often confronted with a
poor quality of life and/or stress due to their disease. Yong-
hui Ma and colleagues state that a “patient’s autonomy
may be compromised by their stress and desperation,
affecting their ability to give informed consent.” We chal-
lenge the idea that the capacity to consent of “desperate” or
vulnerable patients would be compromised regarding FMT
decisions. With an appeal to the principle of respect for
patients’ autonomy, patients are usually presumed capable
of providing informed consent unless demonstrated other-
wise. There is no reason to believe that patients suffering
from IBD lack understanding, appreciation, reasoning, or
decisional capacities related to the specific task of deciding
for or against a treatment offer. Clinicians routinely treat
patients suffering from—arguably—more severe and/or
life-threatening diseases, who are perfectly capable of giv-
ing (presumed) informed consent, and researchers legiti-
mately include these patients in research studies based on
their voluntary informed consent.
Informed consent generally presupposes three ele-
ments: capacity to consent, voluntariness, and information
(Bunnik, Janssens, and Schermer 2013). It is not capacity to
consent but inadequate information that may pose difficul-
ties in regard to FMT. Despite the description of FMT in
ancient medical texts and its documented uses in veteri-
nary medicine, the utilization of FMT in modern health
care is relatively recent. Its clinical demand has greatly
outpaced the understanding of its risks and benefits that
would have typically developed through multiple phases
of clinical trials required to bring a drug to market. Data
regarding its long-term safety in humans are particularly
lacking.
While FMT may seem “natural” and safe (Kahn, Gora-
wara-Bhat, and Rubin 2012), and possibly even “frugal,”
researchers are concerned about lasting effects that donors’
intestinal microbes may have on FMT recipients. For exam-
ple, the gut microbiota has been shown to be a likely trans-
ferrable agent of risk or phenotype in multiple disorders,
including obesity (Turnbaugh et al. 2006), cardiovascular
disease, and autoimmune disorders, such as type 1 diabe-
tes. Also, the gut microbiota has been found to interact
with the central nervous system and to affect brain chemis-
try and behaviors (Bercik et al. 2011). Theoretically, FMT
could entail the transmission of anxiety and depression,
autism, or neurological conditions, such as Parkinson’s
disease. However, most of these effects have only been
examined in preclinical (i.e., animal) studies.
Though all risks should be disclosed during the
informed consent process, we question whether in practice
most doctors offering FMT for recurrent CDIs refer to pre-
clinical research, including animal studies, when discus-
sing potential long-term risks of FMT with patients. The
risks of FMT may be inadequately appreciated by clini-
cians who are not familiar with preclinical studies, and
thus by their patients as well.
Over the next couple of years, it is imperative that data
on potential long-term safety risks of FMT are gathered.
This can be done at relatively low cost through data regis-
tries, such as the national registry that is being spear-
headed by the American Gastroenterological Association
to track the long-term benefits and risks of FMT, compare
the effectiveness of various modes of FMT delivery (e.g.,
colonoscopy, enema, nasogastric tube), and develop stand-
ards of care (Kelly et al. 2017). There is broad international
support for the development and maintenance of local,
regional, national, and international registries to trace
potential long-term side effects from FMT, and to provide
more (short- and long-term) information about the clinical
use and utility of FMT. Complementary to clinical trials,
data registries can support the wider clinical implementa-
tion of FMT for the treatment of CDIs, and in the future
possibly also for other indications.
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Until that time, we encourage treating clinicians to
underline the investigational character of the treatment,
inform patients about other treatment options that are
FDA approved, and to discuss the implications of basic
and translational studies to potential FMT patients to
ensure informed consent. In the informed consent process,
health professionals should counter the seemingly frugal
and risk-free image of FMT by clearly indicating the
unknowns and possible risks. While we agree with Yong-
hui Ma and colleagues that desperation of patients should
not be a basis for treatment decisions about FMT, we do
contend that—on the condition of proper informed con-
sent—it can be perfectly reasonable for some patients with
CDI to pursue FMT. &
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